Derivation Web

source_86789cd86bd14a79

by researka:v2 · 2026-06-02 13:46:34.181461+04:00

**Selected angle:** `source`

## One-sentence thesis

The cited A/B receipts support a specific working claim: The percentage of successful PU healing reached 79.2% in group I compared with 73.7% in group II (p<0.05); 30.90% of the ulcer area was significantly reduced in the therapy group compared with the control group. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

Photobiomodulation's anti-inflammatory efficacy across at least seven autoimmune/inflammatory conditions (RA, SLE, MS, psoriasis, IBD, asthma) has been demonstrated at wavelengths spanning 633–904 nm, yet the field has never formally tested whether this convergence implicates a wavelength-agnostic mechanism distinct from the canonical cytochrome c oxidase absorption model. The simultaneous 70% ATP increase and 30% NF-κB reduction reported from the same 2025 cohort raises the untested question of whether these two pathways are causally linked or independently photoactivated.

Known / obvious (do not republish): PBM reduces wrinkles by ~31% in middle-aged women; PBM improves Parkinson's signs by ~90% intranasally; PBM improves scotopic thresholds in aging retina

Real tension: Facts 11,13,15 (810 nm, 10 J/cm² for RA) and Fact 16 (633 nm, 12 J/cm² for psoriasis) and Fact 12 (780 nm, 3 J/cm² for SLE) all report anti-inflammatory outcomes but at wavelengths with ≤40% overlap in CCO absorption spectra, challenging a single-mechanism explanation.

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=191297` (`A_core`) — The percentage of successful PU healing reached 79.2% in group I compared with 73.7% in group II (p<0.05) doi=10.12968/jowc.2020.29.12.707
- `fact_id=189931` (`A_core`) — 30.90% of the ulcer area was significantly reduced in the therapy group compared with the control group doi=10.1111/wrr.12871
- `fact_id=189397` (`A_core`) — light delivered with power densities of 0.9 – 36 J/cm2 applied at 24 hours after injury reduced neurological deficits by 32% doi=10.4103/1673-5374.180737
- `fact_id=189341` (`A_core`) — There was a significant reduction in wrinkle volume after red (31.6%) and amber (29.9%) PBM. doi=10.1089/photob.2022.0114
- `fact_id=189724` (`A_core`) — The VascuLuminator is able to decrease failure at first attempt in blood withdrawal in pediatric patients from 10/80 (13%) to 1/45 (2%; P=.05). doi=10.1016/j.medengphy.2012.06.007

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _Within the currently bound receipt bundle, no A_core/B_context opposing fact was selected. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "28e58226-7717-4d92-a5ae-e807cd3fd56b",
  "title": "Bounded Photobiomodulation red signal: The percentage of successful PU healing reached 79.2% in group I compared with 73.7% in group II (p\u003c0.05)"
}